Peter Marks on creating Operation Warp Speed, but for rare diseases; EU orders Illumina to divest cancer diagnostics firm Grail

Taking stock of the drug industry, from the lab to the medicine chest

October 12, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Susan Walsh-Pool/Getty Images STAT+ | Peter Marks on creating Operation Warp Speed, but for rare diseases As the gene therapy field struggles, the FDA is launching a warp speed program to get potent treatments for rare diseases to market By Jason Mast STAT+ | EU orders Illumina to divest cancer diagnostics firm Grail The move Thursday was the latest regulatory action against the 2021 acquisition, which is also facing challenges from the U.S. By Andrew Joseph STAT+ | Life sciences deals on track to hit lowest point since 2017 The problem, analysts and investors say, is that generalist investors who steer trillions of dollars of capital have soured on biotech. By Allison DeAngelis

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser